
|Articles|July 1, 2001
- Pharmaceutical Executive-07-01-2001
- Volume 0
- Issue 0
Submerged
Author(s)Wayne Koberstein
Is the pharmaceutical industry surrounded by its critics? Can the industry be liberated from the moral bind others want to impose on it? Those are questions I asked and attempted to answer in two recent editorials (PE April and June 2001). Actually, the simple answer was yes to both. But other answers prove more complex.
Advertisement
Articles in this issue
almost 25 years ago
Pharmacies: OTC Price Warsalmost 25 years ago
One Disease at a Timealmost 25 years ago
Overview of the Industry: A World of Opportunitiesalmost 25 years ago
The Power Shiftalmost 25 years ago
A Giant Stumblesalmost 25 years ago
Overruled: No More Dual Pricingalmost 25 years ago
Generic ThreatAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
The New Healthy Aging Imperative and What It Means for Pharma
2
Why ‘Fully Staffed’ Field Teams Still Miss Revenue Targets—and How Pharma Can Fix It
3
EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval
4
Reading Between the Lines: Closing the T1D Misdiagnosis Gap
5




